{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:11:53Z","timestamp":1770484313573,"version":"3.49.0"},"reference-count":30,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>Meningococcal disease incidence is highest in children younger than 2 years of age, yet there is no US-licensed vaccine for this age group. A phase III study evaluated the immunogenicity and safety of an investigational Haemophilus influenzae type b (Hib)\u2013Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                  <jats:p>A total of 4180 infants were randomly assigned to receive the HibMenCY at the ages of 2, 4, 6, and 12 to 15 months or the licensed Hib tetanus toxoid conjugate vaccine (ActHIB) at 2, 4, and 6 months and Hib conjugated to N meningitidis outer membrane protein (PedvaxHIB) at 12 to 15 months. Routinely scheduled vaccines were coadministered. Serum bactericidal activity using human complement and anti\u2013polyribosylribitol phosphate antibodies were assessed in 991 subjects. Local and systemic adverse reactions were recorded for 4 days after each dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>The percentage of HibMenCY recipients with serum bactericidal assay using human complement titers of 1:8 or higher after dose 3 was 98.8% for N meningitidis serogroup C (MenC) and 95.8% for N meningitidis serogroup Y (MenY). After dose 4, the percentages were 98.5% and 98.8%, respectively. The percentage of HibMenCY recipients with postdose 3 anti-polyribosylribitol phosphate antibody levels of \u22651.0 \u03bcg\/mL was noninferior to that of control (96.3% vs 91.2%). After dose 4, MenC and MenY serum bactericidal assay using human complement antibody titers increased 12-fold over pre\u2013dose 4 levels. Incidence of pain, redness, and swelling at the HibMenCY injection sites tended to be lower than with Hib type b after the first 3 doses and after the fourth dose. Rates of systemic symptoms were similar across groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>The HibMenCY was immunogenic against MenC and MenY and induced anti\u2013polyribosylribitol phosphate antibody levels noninferior to those of licensed Hib conjugate vaccine. The safety profile of the HibMenCY was clinically acceptable and comparable to Hib conjugate vaccine.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2009-2992","type":"journal-article","created":{"date-parts":[[2011,5,31]],"date-time":"2011-05-31T00:13:51Z","timestamp":1306800831000},"page":"e1375-e1385","source":"Crossref","is-referenced-by-count":25,"title":["Immunogenicity and Safety of <i>H influenzae<\/i> Type b\u2013<i>N meningitidis<\/i> C\/Y Conjugate Vaccine in Infants"],"prefix":"10.1542","volume":"127","author":[{"given":"Kristina A.","family":"Bryant","sequence":"first","affiliation":[{"name":"University of Louisville, Louisville, Kentucky;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S.","family":"Marshall","sequence":"additional","affiliation":[{"name":"University of Louisville, Louisville, Kentucky;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin D.","family":"Marchant","sequence":"additional","affiliation":[{"name":"Boston University Medical Center, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noris","family":"Pavia-Ruiz","sequence":"additional","affiliation":[{"name":"Hospital Infantil De Mexico Federico Gomez, Mexico City, Mexico;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Nolan","sequence":"additional","affiliation":[{"name":"Murdoch Children's Research Institute and University of Melbourne School of Population Health, Melbourne, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Rinderknecht","sequence":"additional","affiliation":[{"name":"Iowa Health Physicians, Waukee, Iowa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Blatter","sequence":"additional","affiliation":[{"name":"Primary Physicians Research, Pittsburgh, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Aris","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium, and King of Prussia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Lestrate","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium, and King of Prussia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Boutriau","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium, and King of Prussia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard R.","family":"Friedland","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium, and King of Prussia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Miller","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium, and King of Prussia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2011,6,1]]},"reference":[{"key":"2021120900213639100_B1","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"2021120900213639100_B2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2021120900213639100_B3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/INF.0b013e3181c3ce88","article-title":"Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants","volume":"29","author":"Marchant","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"51","key":"2021120900213639100_B4","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1016\/j.vaccine.2007.10.013","article-title":"A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants","volume":"25","author":"Nolan","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"2021120900213639100_B5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/INF.0b013e3181cdd379","article-title":"Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age","volume":"29","author":"Marshall","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2021120900213639100_B6","first-page":"2592","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2008","volume":"33","author":"Australian Meningococcal Surveillance Programme","year":"2009","journal-title":"Commun Dis Intell"},{"key":"2021120900213639100_B7","unstructured":"Casos por entidad federativa de Enfermedades Transmisibles hasta la semana epidemiol\u00f3gica 33 del 2010 Vigilancia Epidemiol\u00f3gica Semana 34, 2010. Available at: www.dgepi.salud.gob.mx\/boletin\/2010\/sem34\/pdf\/cua10.1.pdf. Accessed September 15, 2010"},{"issue":"5","key":"2021120900213639100_B8","first-page":"438","article-title":"Meningococcal disease caused by Neisseria meningitidis: epidemiological, clinical, and preventive perspectives [in Spanish]","volume":"46","author":"Almeida-Gonzales","year":"2004","journal-title":"Salud Publica Mex"},{"issue":"3","key":"2021120900213639100_B9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1179\/016164110X12644252260754","article-title":"Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention","volume":"32","author":"S\u00e1fadi","year":"2010","journal-title":"Neurol Res"},{"key":"2021120900213639100_B10","article-title":"Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate). Product information as of November 2009","author":"ActHIB"},{"issue":"10","key":"2021120900213639100_B11","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","article-title":"Reporting of noninferiority and equivalence randomized trials","volume":"295","author":"Piaggio","year":"2006","journal-title":"JAMA"},{"issue":"18","key":"2021120900213639100_B12","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1001\/jama.298.18.2155","article-title":"Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States","volume":"298","author":"Roush","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"2021120900213639100_B13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6","key":"2021120900213639100_B14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"3","key":"2021120900213639100_B15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0b013e31818e037d","article-title":"Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants","volume":"28","author":"Perrett","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021120900213639100_B16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"issue":"6","key":"2021120900213639100_B17","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/jcm.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay","volume":"32","author":"Gheesling","year":"1994","journal-title":"J Clin Microbiol"},{"issue":"6","key":"2021120900213639100_B18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/infdis\/149.6.1034","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"149","author":"Anderson","year":"1984","journal-title":"J Infect Dis"},{"issue":"6","key":"2021120900213639100_B19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"147","author":"K\u00e4yhty","year":"1983","journal-title":"J Infect Dis"},{"key":"2021120900213639100_B20","unstructured":"Vaccines and Related Biological Products Advisory Committee. FDA briefing document for Pentacel: diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate) vaccine combined. Available at: www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4275B1-02.pdf. Accessed February 28, 2010."},{"issue":"9114","key":"2021120900213639100_B21","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(97)07456-4","article-title":"Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens","volume":"351","author":"Lagos","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"2021120900213639100_B22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4269\/ajtmh.2000.62.485","article-title":"Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine","volume":"62","author":"Fernandez","year":"2000","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"2021120900213639100_B23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/CDLI.8.6.1115-1119.2001","article-title":"Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate)","volume":"8","author":"Romero-Steiner","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"issue":"9","key":"2021120900213639100_B24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/00006454-200209000-00007","article-title":"Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants","volume":"21","author":"Campbell","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"2021120900213639100_B25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.vaccine.2004.06.052","article-title":"Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus infuenzae type b vaccines","volume":"23","author":"Huebner","year":"2004","journal-title":"Vaccine"},{"issue":"50","key":"2021120900213639100_B26","first-page":"1318","article-title":"Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines (PedvaxHIB and Comvax)","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2021120900213639100_B27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/INF.0b013e3181fcb2bf","article-title":"Immunogenicity and safety of an investigational combined Haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine","volume":"30","author":"Nolan","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2021120900213639100_B28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/clinids\/7.4.504","article-title":"Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes","volume":"7","author":"Frasch","year":"1985","journal-title":"Rev Infect Dis"},{"issue":"6","key":"2021120900213639100_B29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/INF.0b013e31805d7f17","article-title":"Use of combination vaccines is associated with improved coverage rates","volume":"26","author":"Marshall","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021120900213639100_B30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/INF.0b013e318187d047","article-title":"Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population","volume":"28","author":"Happe","year":"2009","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/6\/e1375\/846113\/zpe006110e1375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/6\/e1375\/846113\/zpe006110e1375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T05:58:35Z","timestamp":1639029515000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/127\/6\/e1375\/30035\/Immunogenicity-and-Safety-of-H-influenzae-Type-b-N"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,1]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,6,1]]},"published-print":{"date-parts":[[2011,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2009-2992","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,1]]}}}